Table 3. Association between selected characteristics and SeroResponse proportion (S0 to S2) (n = 46).
| Crude | Multivariate model 1a | Multivariate model 2b | Multivariate model 3c | Multivariate model 4d | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Category | sR (%) | OR (95%CI) | P | OR (95%CI) | P | OR (95%CI) | P | OR (95%CI) | P | OR (95%CI) | P | |
| Age | 60–83/36–59 | 52/60 | 0.73 (0.23–2.28) | 0.59 | 1.58 (0.37–6.74) | 0.53 | 1.52 (0.37–6.37) | 0.56 | 0.71 (0.18–2.80) | 0.63 | 0.96 (0.22–4.15) | 0.95 |
| Gender | Female/Male | 47/72 | 0.34 (0.10–1.18) | 0.09 | 0.60 (0.14–2.63) | 0.50 | ||||||
| Underlying disease Lymphoma Acute leukemia Myeloma |
+/− +/− +/− |
33/74 69/51 75/53 |
0.18(0.05–0.61) 2.13 (0.55–8.21) 2.71 (0.49–15.1) |
0.01 0.27 0.25 |
0.09 (0.01–1.12) 0.40 (0.03–4.83) 0.39 (0.02–6.96) |
0.06 0.47 0.52 |
0.08 (0.01–0.95) 0.40 (0.03–4.76) 0.47 (0.03–7.71) |
0.05 0.47 0.59 |
0.43 (0.08–2.18) | 0.31 | ||
| Chemotherapy Steroid Immunosuppressive Agents Anticancer agents* Rituximab |
+/− +/− +/− |
41/76 40/58 30/69 10/68 |
0.22 (0.06–0.76) 0.48 (0.07–3.17) 0.21 (0.06–0.75) 0.05 (0.01–0.45) |
0.02 0.45 0.02 0.01 |
0.75 (0.11–4.93) 0.42 (0.04–4.49) 0.56 (0.08–3.84) 0.08 (0.01–0.86) |
0.76 0.47 0.55 0.04 |
0.09 (0.01–1.04) | 0.05 | ||||
Logistic regression model. CI: confidence interval; OR: odds ratio; aModel include age, sex, lymphoma, acute leukemia, and myeloma; bModel include age, lymphoma, acute leukemia and myeloma. cModel include age, steroid, immunosuppressive agents, anticancer agents and rituximab; dModel include age, lymphoma and rituximab; *Anticancer agents does not include rituximab.